These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29807137)

  • 1. Proteomic approaches unravel the intricacy of secreted proteins of Leishmania: An updated review.
    Garg G; Singh K; Ali V
    Biochim Biophys Acta Proteins Proteom; 2018 Aug; 1866(8):913-923. PubMed ID: 29807137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering the Leishmania exoproteome: what we know and what we can learn.
    Corrales RM; Sereno D; Mathieu-Daudé F
    FEMS Immunol Med Microbiol; 2010 Feb; 58(1):27-38. PubMed ID: 19807787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shotgun proteomics to unravel the complexity of the Leishmania infantum exoproteome and the relative abundance of its constituents.
    Braga MS; Neves LX; Campos JM; Roatt BM; de Oliveira Aguiar Soares RD; Braga SL; de Melo Resende D; Reis AB; Castro-Borges W
    Mol Biochem Parasitol; 2014 Jun; 195(1):43-53. PubMed ID: 25017697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic approaches for drug discovery against tegumentary leishmaniasis.
    Negrão F; Eberlin MN; Giorgio S
    Biomed Pharmacother; 2017 Nov; 95():577-582. PubMed ID: 28869896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics advances in the study of Leishmania parasites and leishmaniasis.
    de Jesus JB; Mesquita-Rodrigues C; Cuervo P
    Subcell Biochem; 2014; 74():323-49. PubMed ID: 24264252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding Leishmania parasites through proteomics and implications for the clinic.
    Sundar S; Singh B
    Expert Rev Proteomics; 2018 May; 15(5):371-390. PubMed ID: 29717934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative secretome analysis unravels new secreted proteins in Amphotericin B resistant Leishmania donovani.
    Garg G; Ali V; Singh K; Gupta P; Ganguly A; Sahasrabuddhe AA; Das P
    J Proteomics; 2019 Sep; 207():103464. PubMed ID: 31357030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of proteomics of Leishmania spp. to the understanding of differentiation, drug resistance mechanisms, vaccine and drug development.
    Paape D; Aebischer T
    J Proteomics; 2011 Aug; 74(9):1614-24. PubMed ID: 21621022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentially modulated proteins associated with Leishmaniasis-a systematic review of in-vivo and in-vitro studies.
    Ranjan R; Das P; Vijayakumar S
    Mol Biol Rep; 2020 Nov; 47(11):9159-9178. PubMed ID: 33113081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Proteomics to Understand How Leishmania Parasites Survive inside the Host and Establish Infection.
    Veras PS; Bezerra de Menezes JP
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of heparan sulfate in host macrophage infection by
    Maciej-Hulme ML; Skidmore MA; Price HP
    Biochem Soc Trans; 2018 Aug; 46(4):789-796. PubMed ID: 29934302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmaniasis: efflux pumps and chemoresistance.
    Leandro C; Campino L
    Int J Antimicrob Agents; 2003 Sep; 22(3):352-7. PubMed ID: 13678842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease inhibitors in potential drug development for Leishmaniasis.
    Das P; Alam MN; Paik D; Karmakar K; De T; Chakraborti T
    Indian J Biochem Biophys; 2013 Oct; 50(5):363-76. PubMed ID: 24772958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The LABCG2 Transporter from the Protozoan Parasite Leishmania Is Involved in Antimony Resistance.
    Perea A; Manzano JI; Castanys S; Gamarro F
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3489-96. PubMed ID: 27021316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exoproteome dynamics in Leishmania infantum.
    Santarém N; Racine G; Silvestre R; Cordeiro-da-Silva A; Ouellette M
    J Proteomics; 2013 Jun; 84():106-18. PubMed ID: 23558030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Studies on the parasite Leishmania in the post-genomic era].
    Ouellette M; Olivier M; Sato S; Papadopoulou B
    Med Sci (Paris); 2003 Oct; 19(10):900-9. PubMed ID: 14612998
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Esteves S; Costa I; Luelmo S; Santarém N; Cordeiro-da-Silva A
    Microorganisms; 2022 Dec; 10(12):. PubMed ID: 36557688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating genomics and proteomics permits identification of immunodominant antigens associated with drug resistance in human visceral leishmaniasis in India.
    Singh N; Sundar S
    Exp Parasitol; 2017 May; 176():30-45. PubMed ID: 28263760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of molecular methods for Leishmania control.
    Singh S; Dey A; Sivakumar R
    Expert Rev Mol Diagn; 2005 Mar; 5(2):251-65. PubMed ID: 15833054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targets and pathways for the treatment of visceral leishmaniasis.
    Jain V; Jain K
    Drug Discov Today; 2018 Jan; 23(1):161-170. PubMed ID: 28919438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.